Study data show Afrezza provides greater improvement in postprandial glucose control than insulin aspart
WESTLAKE VILLAGE, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD) announced today that “Improved Postprandial Glucose with Inhaled Technosphere® Insulin Compared to Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study” has been published online in Diabetes Technology & Therapeutics.
The STAT study is the first randomized, controlled study to assess diabetes control using continuous glucose monitoring and Afrezza® in individuals with type 1 diabetes. The dual primary endpoints were:
- 24-hour glucose time-in-range (TIR)
- Postprandial glucose excursions (PPGE), defined as the peak increase in glucose in the 1 to 4 hour post-meal period
/EIN News/ — This trial, supported by funding from MannKind Corporation, was a pilot study led by investigators at the Barbara Davis Center for Diabetes.
Compared to standard of care for mealtime therapy, the per-protocol use of Afrezza (i.e. supplemental doses 1 and/or 2 hours post-meal), on average demonstrated:
- Significantly increased glucose TIR by approximately 2 hours per day
- Significantly reduced time in hyperglycemia > 180 mg/dL
- Significantly lower PPGE 1 to 4 hours post-meal
- Significant reductions in glucose as early as 60 minutes following Afrezza dose
- Less hypoglycemia (as measured by time spent less than 60 mg/dL); notably, the average Afrezza-treated individual spent approximately 3 minutes per day with blood glucose values less than 50 mg/dL compared to approximately 12 minutes per day for aspart-treated individuals
This is the first of a number of planned randomized trials, intended to evaluate the potential benefits of Afrezza (Technosphere Insulin) compared to the standard of care for mealtime plus basal insulin.
“I am very pleased to have helped develop the design of this novel trial (STAT) at the Barbara Davis Center for Diabetes, performed as a collaborative multi-center clinical trial with several other investigators around the country,” stated Halis Kaan Akturk, M.D., Assistant Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver and the principal investigator of the STAT study. “With the peer review publication of these data in Diabetes Technology & Therapeutics, we feel that our data supporting the unique time-action profile of Technosphere Insulin (Afrezza®) is helping us to better understand the potential advantages of a truly rapid-acting insulin delivery system for improving control of mealtime glucose. Specifically, individuals with type 1 diabetes, treated with Technosphere Insulin, demonstrated lower blood glucose as early as one hour after meals and, based on our analysis, supplemental dosing with Technosphere Insulin further improved the glucose control measured after meals. These data are the first to demonstrate that individuals living with type 1 diabetes may achieve significant improvement in postprandial glucose with Technosphere Insulin as a mealtime insulin, compared to standard of care, rapid-acting insulin analogs.”
“These new data significantly advance our understanding of the potential clinical benefits of Afrezza therapy for those living with type 1 diabetes,” stated David Kendall, M.D., Chief Medical Officer of MannKind Corporation. “We believe one of the key limitations to optimal glucose control and achieving better outcomes for people living with diabetes is their ability to control mealtime glucose levels. These data generated to date further support the view that Afrezza has the potential to be the treatment of choice for those individuals with diabetes who require alternatives that further improve mealtime glucose control. The completion of this proof-of-concept trial and peer-reviewed publication allows for broad sharing of these data with diabetes healthcare professionals.”
The published research can be found online at https://www.liebertpub.com/doi/10.1089/dia.2018.0200
About MannKind Corporationwww.mannkindcorp.com.
Company Contact: [email protected]
- Leaked WHO Documents Reveal Antiviral Drug Remdesivir Failed First Clinical Trial
- The new faces of Type 1 diabetes
- Nearly 90 Percent of Coronavirus Patients Put on Ventilators in New York's Largest Health System Died, Study Shows
- Most children with coronavirus have mild symptoms, recover within 2 weeks: study
- Study links obesity to severity of disease, death in young patients
- Remdesivir Eases Covid-19 Symptoms in Monkeys in 12 Hours, Small Preliminary Study Shows
- Preliminary study results suggest the drug Trump touted doesn't work for very sick coronavirus patients
- Coronavirus Pandemic: Early Data Shows Anti-Viral Drug Effective Against COVID-19
- 80% of the sites pushing coronavirus conspiracies were publishing other toxic misinformation before this crisis
- Coronavirus: China cancelling clinical trials for lack of test subjects as case numbers fall
- Kaiser study finds coronavirus seriously affects people regardless of age
- Almost All Patients Hospitalized for Coronavirus Had Chronic Health Issues, Large Study Finds
- Patients start infection spread before symptoms set in: Study
- More proof the lockdown is working: Number of Britons with coronavirus symptoms plummets 71% in a fortnight as data-tracking app shows just under 600,000 Brits now have tell-tale signs of the killer infection
- Asthma is absent among top Covid-19 risk factors, early data shows
- Pupil and a relative in Devon are among three new coronavirus cases in UK as infection toll hits 39: Eleven schools shut after staff or parents fall ill, Kent NHS worker is diagnosed and Hertfordshire cancer clinic tests 20 patients after medic feared infe
- Study suggests ACEI/ARB safe of COVID-19 patients with hypertension
- Coronavirus live updates: 840 sailors from Navy’s Theodore Roosevelt aircraft carrier test positive
- Two Big Studies Say There Are Way More Coronavirus Infections Than We Think. Scientists Think They're Wrong.
- Two Antibody Studies Say Coronavirus Infections Are More Common Than We Think. Scientists Are Mad.
Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics have 868 words, post on world.einnews.com at September 13, 2018. This is cached page on Talk Vietnam. If you want remove this page, please contact us.